CTOs on the Move

Metacrine

www.metacrine.com

 
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.metacrine.com
  • 3985 Sorrento Valley Boulevard Suite C
    San Diego, CA USA 92121
  • Phone: 858.369.7800

Executives

Name Title Contact Details

Funding

Metacrine raised $36M on 08/05/2015
Metacrine raised $65M on 06/05/2018

Similar Companies

AB Scientific

Welcome to AB Scientific. Suppliers of innovative products to Pharmaceutical, Clinical and Life Science laboratories in the UK and Ireland.

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

Elevation Oncology

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor`s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.

Oncorus

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded by well-known biotechnology entrepreneurs and is backed by MPM Capital. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. We are located in Kendall Square, Cambridge, MA.

Kamiya Biomedical Company

Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.